ArticleFrontiers in immunology2025
Case Report: A Chinese woman with primary Sjögren's syndrome presented with simultaneous involvement of the cerebral and coronary arteries as initial symptoms.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary Sjögren's syndrome (pSS) is a heterogeneous autoimmune disorder that may be associated with systemic manifestations such as pulmonary or articular involvement.Compared to other autoimmune diseases, vascular injury and accelerated atherosclerosis in pSS are less studied. Case presentation: A 51-year-old woman presented with a 2-month history of dizziness, chest tightness, and exertional dyspnea. Vascular imaging revealed multifocal stenoses in the left anterior descending coronary artery (70%), bilateral middle cerebral arteries, right anterior cerebral artery, and left posterior cerebral artery. Her only traditional cardiovascular risk factor was hypertension, and she reported only mild xerostomia. Serology showed anti-SSA positivity. Schirmer's test was abnormal, and a labial gland biopsy confirmed focal lymphocytic sialadenitis (≥1 foci/4 mm²), leading to a pSS diagnosis per 2016 ACR-EULAR criteria. She responded favorably to a combination of immunomodulators (hydroxychloroquine and total glucosides of paeony), antiplatelet therapy, and statins, with symptom resolution at follow-up. Conclusion: This case represents an exceptionally rare documented instance of pSS simultaneously affecting both cerebral and coronary arterial systems. It underscores that severe multifocal arterial stenosis can present as the initial manifestation of this disease, even in the absence of prominent dryness symptoms. This highlights the necessity for vascular assessment in pSS patients and the urgency of conducting autoimmune evaluations in cases of unexplained multivessel arteriopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.